Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for…

Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug.23, 2024(GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 trial with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). “We have achieved a major milestone, full enrollment in our Phase 1, Safety Trial in the U.S.” said Diane Tang-Liu, PhD, CEO, President...

Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030…

Key Takeaways from the Chemotherapy Drugs Market Report Key Takeaways from the Chemotherapy Drugs Market Report To read more about the latest highlights related to the chemotherapy drugs market, get a snapshot of the key highlights entailed in the Global Chemotherapy Drugs Market Report Chemotherapy Drugs Overview Chemotherapy drugs are powerful medications used to treat cancer by targeting and destroying rapidly dividing cells, a hallmark of cancerous growth. These drugs can...

Innocan Pharma's Subsidiary BI Sky Global Successfully Completes FDA MoCRA…

The Company further announced that following a thorough evaluation of BI's manufacturing controls and raw materials, all its products successfully met the stringent quality standards set by the FDA, fulfilling all compliance requirements necessary for the completion of MoCRA registration. The Company further announced that following a thorough evaluation of BI's manufacturing controls and raw materials, all its products successfully met the stringent quality standards set by the FDA…

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, August 22, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 13,000 divided into 13,000 new shares with a nominal value of DKK 1...

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron…

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and olderThe KP.2 adaptation is based on FDA guidance, which stated that KP.2 is the preferred strain for COVID-19 vaccines for the US 2024-2025 fall and winter season, if feasibleShipping will begin immediately to ensure robust supply and rapid access of this season's vaccine in pharmacies, hospitals, and clinics across the country ...

Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But…

In its decision, MHRA confirms what the scientific community and multiple other health regulatory agencies have long known — lecanemab is safe, effective and beneficial for people in the early stages of Alzheimer's or living with mild cognitive impairment (MCI). The U.K. joins the U.S., China, South Korea, Israel, Hong Kong and Japan in its approval of Leqembi. In its decision, MHRA confirms what the scientific community and multiple other health regulatory agencies have long known —…

KFSHRC Sets New Global Standards with VR Technology at AMEE 2024

RIYADH, Saudi Arabia, Aug.22, 2024(GLOBE NEWSWIRE) -- By continuously adopting new technologies, KFSHRC ensures that its trainees are well-prepared for today's medical challenges and equipped with the skills and knowledge needed to lead the future of medicine. These technologies bridge the gap between theory and practice and prepare healthcare professionals to lead in an increasingly complex and technology-driven healthcare landscape.King Faisal Specialist Hospital & Research...

Trudell Medical Limited expanding into respiratory diagnostics with agreement to…

The purchase is subject to court approval and is expected to close in 8-12 weeks. The acquisition will expand Trudell Medical's already strong market position in aerosol drug delivery and lung health devices to include respiratory diagnostics. The purchase is subject to court approval and is expected to close in 8-12 weeks. The acquisition will expand Trudell Medical's already strong market position in aerosol drug delivery and lung health devices to include respiratory diagnostics. Trudell...

Speaking Valves Market worth $128 million by 2029 driven by Emerging Tech…

Browse in-depth TOC on "Speaking Valves Market " Browse in-depth TOC on "Speaking Valves Market " 140 - Tables50 - Figures173 - Pages Coloplast A/S: Market Leader in Speaking Valves Coloplast A/S ( Denmark ) emerged as the leading player in the global speaking valves market in 2023. The company maintains a strong presence acrossEurope,North America, andAsia, driven by its significant investments in research and development. Coloplast's...

Optellum showcases AI-powered precision lung interventions at AABIP 2024

Minimally invasive endobronchial biopsies, using robotic bronchoscopes under advanced imaging guidance, are state-of-the-art in lung tissue diagnosis. Combining such devices with the power of Optellum's Virtual Nodule Clinic AI platform will transform the precision, speed, and efficiency of the lung cancer care pathway. Nodule programs powered by Optellum's AI platform have been shown to efficiently increase the volume of patients [1] and enable clinicians to make more informed decisions about…

U.K. Hospitality Industry Faces Significant Challenges Amid Labour Shortages and…

Employee morale is also suffering, with almost half of managers acknowledging the negative impact of staff shortages. Primary consequences of these shortages are cited as increased workloads (73%) and higher employee turnover (60%). Customer experience is reported to be deteriorating as a result, with half of respondents noting longer waiting times and a concerning 41% observing a decline in the quality of service. Employee morale is also suffering, with almost half of managers acknowledging...

Oblique Therapeutics has entered a research collaboration agreement with Eli…

The parties already have an existing agreement in place (signed in November 2023) and this agreement expands the collaboration between the companies to a second high-value target. The parties already have an existing agreement in place (signed inNovember 2023 ) and this agreement expands the collaboration between the companies to a second high-value target. " We are delighted to expand the collaboration between our companies and together create new science to address the unmet medical…

BRITISH BEAUTY INDUSTRY'S RESILIENCE REINFORCED BY MARKET GROWTH AND FORECASTED…

- The beauty industry's annual growth rate is forecasted to be higher than the national average in 2024, expected to peak at 3% YOY. - The beauty industry's annual growth rate is forecasted to be higher than the national average in 2024, expected to peak at 3% YOY. LONDON , Aug. 22, 2024 /PRNewswire/ -- The British beauty industry grew by an impressive 11 per cent last year – with signs it is shaking off the triple hangovers of Brexit, Covid and the cost of living crisis, new...

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680…

Vibrance-2 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of ALKS 2680 in adults with NT2. Participants will be randomized to receive one of three doses of ALKS 2680 (10 mg, 14 mg or 18 mg) or placebo to be taken once-daily for eight weeks. The primary endpoint will assess whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone, as measured by the…

Zymeworks Announces Participation in Upcoming Investor Conferences

Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 4 at 8:45 am Eastern Time (ET) in Boston, MA.Morgan Stanley 22 ndAnnual Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 5 at 7:00 am ET in New York, NY.H.C. Wainwright 26 thAnnual Global Investment Conference: Zymeworks' management will participate in one-on-one meetings and a...

Stratus Medical Announces Exclusive Distribution Agreement with Edge Medical for…

Edward Yoon, MD, Chief of Interventional Radiology, Hospital for Special Surgery located in New York City, commented "I am excited for the opportunity to share my personal experience with NIMBUS with my colleagues in the United Kingdom. I have been using NIMBUS since my Fellowship and delighted with our patient outcomes with this technology. I am appreciative of Stratus Medical who supports professional education in the UK, US, and other countries across the world." Edward Yoon, MD…

Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain

Lecanemab selectively binds to Aβ aggregate species, with preferential activity for toxic Aβ protofibrils[3] (as well as fibrils, which are a major component of Aβ plaques). Lecanemab binds to these aggregate Aβ species to neutralize and clear them from the brain. [4],[5],[6] Lecanemab selectively binds to Aβ aggregate species, with preferential activity for toxic Aβ protofibrils [3] (as well as fibrils, which are a major component of Aβ plaques). Lecanemab binds to these aggregate Aβ species...

Energy Gum Market to Reach $263.4 Million, Globally, by 2035 at 7.9% CAGR…

Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/A04227 Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/A04227 Prime determinants of growth Growth in health consciousness results in consumers participating in sports, gymnastics, yoga, and other workout activities. Energy gum helps maximize performance during workouts, to overcome sleep deprivation and fatigue during late-night work. The surge in the number of middle-aged and young...

AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for…

KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs

PCI Biotech: Invitation to first half interim 2024 results presentation

Invitation to presentation of Sectra's three-month interim report 2024/2025

Vistin Pharma ASA: Second quarter and first half 2024 financial results

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1…

Coway Releases Its New Sustainability Report for FY2023

Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030…

Innocan Pharma's Subsidiary BI Sky Global Successfully Completes FDA MoCRA…

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron…

Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But…

KFSHRC Sets New Global Standards with VR Technology at AMEE 2024

Trudell Medical Limited expanding into respiratory diagnostics with agreement to…

Speaking Valves Market worth $128 million by 2029 driven by Emerging Tech…

Optellum showcases AI-powered precision lung interventions at AABIP 2024

U.K. Hospitality Industry Faces Significant Challenges Amid Labour Shortages and…

Oblique Therapeutics has entered a research collaboration agreement with Eli…

BRITISH BEAUTY INDUSTRY'S RESILIENCE REINFORCED BY MARKET GROWTH AND FORECASTED…

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680…

Zymeworks Announces Participation in Upcoming Investor Conferences

Stratus Medical Announces Exclusive Distribution Agreement with Edge Medical for…

Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain

Energy Gum Market to Reach $263.4 Million, Globally, by 2035 at 7.9% CAGR…